Basic Information
| LncRNA/CircRNA Name | LINP1 |
| Synonyms | NA |
| Region | GRCh38_10:6737382-6739026 |
| Ensemble | ENSG00000223784 |
| Refseq | NR_138480 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | doxorubicin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot |
| Sample | breast cancer tissues, Human breast cancer cells (MDA-MB-231, MDA-MB-468 and MCF7) |
| Expression Pattern | up-regulated |
| Function Description | LINP1 knockdown mitigated breast cancer cell growth by inducing G1-phase cell cycle arrest and apoptosis. LINP1 also promoted breast cancer cell metastasis and influenced the expression of epithelial-mesenchymal transition-related markers. We identified p53 as a regulator of LINP1, and LINP1 overexpression could restore the metastatic effects of p53. Furthermore, LINP1 was upregulated in doxorubicin- and 5-fluorouracil-resistant cells and induced chemoresistance. We also observed that LINP1 enrichment played a critical functional role in chemoresistance by inhibiting chemotherapeutics-induced apoptosis. Moreover, LINP1 in tumors was associated with lower overall survival and disease-free survival. |
| Pubmed ID | 29293402 |
| Year | 2018 |
| Title | Long noncoding RNA LINP1 acts as an oncogene and promotes chemoresistance in breast cancer. |
External Links
| Links for LINP1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |